Results 111 to 120 of about 260,030 (390)

Landscape of KRASG12C, Associated Genomic Alterations, and Interrelation With Immuno-Oncology Biomarkers in KRAS-Mutated Cancers

JCO Precision Oncology, 2022
PURPOSE Promising single-agent activity from sotorasib and adagrasib in KRASG12C-mutant tumors has provided clinical evidence of effective KRAS signaling inhibition. However, comprehensive analysis of KRAS-variant prevalence, genomic alterations, and the
M. Salem, S. El-Refai, W. Sha, A. Puccini, A. Grothey, T. George, Jimmy J. Hwang, B. O'Neil, A. Barrett, Kunal C. Kadakia, L. Musselwhite, D. Raghavan, E. Van Cutsem, J. Tabernero, J. Tie   +14 more
semanticscholar   +1 more source

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Simtuzumab in Combination with FOLFIRI for the Second-Line Treatment of Metastatic KRAS Mutant Colorectal Adenocarcinoma. [PDF]

, 2017
Lessons learnedThe safety profile in the patient groups who received FOLFIRI and simtuzumab did not differ from that in the FOLFIRI and placebo group.The addition of simtuzumab to chemotherapy with FOLFIRI does not improve clinical outcomes in patients ...
Bendell, Johanna, Benson, Al B, Hecht, J Randolph, Verma, Udit, Vyushkov, Dmitry, Yang, Yingsi   +5 more
core   +1 more source

Patient‐specific pharmacogenomics demonstrates xCT as predictive therapeutic target in colon cancer with possible implications in tumor connectivity

Molecular Oncology, EarlyView.
This study integrates transcriptomic profiling of matched tumor and healthy tissues from 32 colorectal cancer patients with functional validation in patient‐derived organoids, revealing dysregulated metabolic programs driven by overexpressed xCT (SLC7A11) and SLC3A2, identifying an oncogenic cystine/glutamate transporter signature linked to ...
Marco Strecker, Keren Zohar, Martin Böttcher, Thomas Wartmann, Henry Freudenstein, Maximilian Doelling, Mihailo Andric, Wenjie Shi, Or Kakhlon, Katrin Hippe, Beatrix Jahnke, Dimitrios Mougiakakos, Franziska Baenke, Daniel Stange, Roland S. Croner, Michal Linial, Ulf D. Kahlert   +16 more
wiley   +1 more source

Incidence Of Kras Mutations In Colon Adenocarcinomas And Its Association With Lymph Node Metastases

Hitit Medical Journal, 2020
Objective: Colon adenocarcinoma, one of the most frequent malignant tumors of the gastrointestinal system, is a major cause of morbidity and mortality. As KRAS mutations are encountered in 30-40% of colorectal carcinomas, a mutation screening is required
Gökhan Varlı, İbrahim Hanifi Özercan, Ebru Önalan   +2 more
doaj  

Heterogeneity and clonal evolution of colorectal cancer

Успехи молекулярной онкологии, 2017
There are a lot of studies that dedicated to genetic differences between the primary tumor and metastases. This becomes relevant not only for molecular biologists for understanding carcinogenesis, but also becoming increasingly important for medical ...
M. Yu. Fedyanin, H. H.-M. Elsnukaeva, S. A. Tjulandin   +2 more
doaj   +1 more source

INFLUENCE OF SOMATIC MUTATIONS OF KRAS, NRAS, BRAF AND MICROSATELLITE INSTABILITY STATUS ON SURVIVAL OF COLORECTAL CANCER PATIENTS WITH PERITONAL CARCINO

Сибирский онкологический журнал, 2020
Purpose: to evaluate the effect of somatic mutations of the KRAS, NRAS, BRAF genes and the status of microsatellite instability on the overall and disease-free survival of patients undergoing cytoreductive surgery with hyperthermic intraperitoneal ...
V. P. Shubin, Yu. A. Shelygin, S. I. Achkasov, O. I. Sushkov, A. A. Ponomarenko, A. I. Arzamastseva, A. S. Tsukanov   +6 more
doaj   +1 more source

KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?

Frontiers in Oncology, 2022
KRAS mutations are among the most commonly occurring mutations in cancer. After being deemed undruggable for decades, KRAS G12C specific inhibitors showed that small molecule inhibitors can be developed against this notorious target.
Sahar F. Bannoura, H. Khan, A. Azmi
semanticscholar   +1 more source

Precision delivery of RAS-inhibiting siRNA to KRAS driven cancer via peptide-based nanoparticles [PDF]

, 2019
Over 95% of pancreatic adenocarcinomas (PDACs), as well as a large fraction of other tumor types, such as colorectal adenocarcinoma, are driven by KRAS activation. However, no direct RAS inhibitors exist for cancer therapy.
Bi, Ye, Brooks, Candace, DeNardo, David G, Fields, Ryan C, Fleming, Timothy, Gillanders, William E, Goedegebuure, S Peter, Hawkins, William G, Krasnick, Bradley A, Pan, Hua, Sankpal, Narendra, Strand, Matthew S, Wetzel, Christopher, Wickline, Samuel A, Zhang, Xiuli   +14 more
core   +1 more source

Feasibility of a ctDNA multigenic panel for non‐small‐cell lung cancer early detection and disease surveillance

Molecular Oncology, EarlyView.
Plasma‐based detection of actionable mutations is a promising approach in lung cancer management. Analysis of ctDNA with a multigene NGS panel identified TP53, KRAS, and EGFR as the most frequently altered, with TP53 and KRAS in treatment‐naïve patients and TP53 and EGFR in previously treated patients.
Giovanna Maria Stanfoca Casagrande, Marcela de Oliveira Silva, Mariana Bisarro dos Reis, Rodrigo de Oliveira Cavagna, Luciane Sussuchi, Icaro Alves Pinto, Natalia Zampieri Pontes, Rodrigo Sampaio Chiarantano, Flavio Augusto Ferreira da Silva, Pedro de Marchi, Letícia Ferro Leal, Rui M. Reis   +11 more
wiley   +1 more source

Target liquid biopsy using “enriched” polymerase chain reaction and DNA melting analysis

Успехи молекулярной онкологии, 2018
Objective: to evaluate the possibility of using a highly sensitive method of “enriched” polymerase chain reaction followed by DNA melting analysis (PCR-DMA) for target liquid biopsy of cancer patients.Materials and methods.
I. V. Botezatu, I. O. Panchuk, A. A. Kolomeytseva, A. A. Fedenko, N. N. Mazurenko, I. V. Tsyganova, O. Yu. Susova, V. N. Kondratova, V. P. Shelepov, A. V. Lichtenstein   +9 more
doaj   +1 more source